Amryt Pharma (AMYT.L, AMYT LN)

  • 319.1
  • 162.8
  • 61.1

    Closing Price (p): 196.0

  • RATING 14/09/17


Company Profile

Formed in 2015, Amryt Pharma acquires, develops and commercialises therapies for orphan (rare) diseases, diseases that have small rates of prevalence among country populations. Amryt is not involved in drug discovery but acquires its pipeline through the acquisition and in-licensing of orphan therapies. The company currently has four assets in its portfolio (AP101, AP102, AP103 and Lojuxta) that are targeting multiple orphan indications. These therapies span both development and commercial stages of the lifecycle. Amryt also reports modest revenues from Imlan, the company's derma-cosmetics range of products. Imlan is considered a non-core part of the company's portfolio.

Major Shareholders%
Athytrium Capital Mgmt27.2
Novelion Therapeutics8.9
EdgePoint Investment Group7.9
Highbridge Capital Mgmt7.2
Software AG-Stiftung6.5